Pharmacogenetics as predictor of sunitinib and mTOR inhibitors toxicity in patients with metastatic renal cell carcinoma (mRCC)

被引：0
|
作者：
Urun, Yuksel
Gray, Kathryn P.
Signoretti, Sabina
McDermott, David F.
Atkins, Michael B.
Lampron, Megan E.
Freedman, Matthew
Choueiri, Toni K.
Pomerantz, Mark M.
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA
[3] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA
[4] Georgetown Lombardi Comprehens Canc Ctr, Washington, DC USA
[5] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4570
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma (mRCC) with severe renal impairment or on haemodialysis
    Josephs, D. H.
    Hutson, T. E.
    Pickering, L. M.
    Larkin, J. M.
    Choueiri, T. K.
    Patel, T. V.
    Mcdermott, D. F.
    Powles, T.
    Harper, P. G.
    Chowdhury, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [2] Skin toxicity of sunitinib: Prospective analysis in patients (pts) with metastatic renal cell carcinoma (mRCC)
    Billemont, B.
    Barete, S.
    Meric, J. B.
    Moguelet, P.
    Frances, C.
    Chosidow, O.
    Goldwasser, F.
    Rixe, O.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [3] Sunitinib safety and tolerability in patients with metastatic renal cell carcinoma (MRCC)
    Ferrari, A.
    Sabbatini, R.
    Maur, M.
    Giovannelli, S.
    Jovic, G.
    Conte, P.
    ANNALS OF ONCOLOGY, 2006, 17 : XI83 - XI83
  • [4] SAFETY PROFILE OF SUNITINIB AND SORAFENIB IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (MRCC)
    Massari, Francesco
    Sperandi, Francesca
    Cricca, Antonia
    Melotti, Barbara
    Martoni, Andrea Angelo
    ANNALS OF ONCOLOGY, 2009, 20
  • [5] CARDIOTOXICITY IN METASTATIC RENAL CELL CARCINOMA (mRCC) PATIENTS TREATED WITH SUNITINIB (SU)
    Ballatore, Valentina
    Prati, Veronica
    Ruatta, Fiorella
    Galizia, Danilo
    Grignani, Giovanni
    Aglietta, Massimo
    Ortega, Cinzia
    ANTICANCER RESEARCH, 2012, 32 (05) : 1876 - 1877
  • [6] Pharmacokinetics (PK) and efficacy of sunitinib in patients with metastatic renal cell carcinoma (mRCC).
    Houk, B. E.
    Amantea, M.
    Motzer, R. J.
    Michaelson, M. D.
    Rini, B. I.
    George, D. J.
    Redman, B. G.
    Hudes, G. R.
    Poland, B.
    Bello, C. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 224S - 224S
  • [7] Sunitinib in patients with cytokine-refiractory metastatic renal cell carcinoma (mRCC)
    George, D. J.
    Michaelson, M. D.
    Rosenberg, J. E.
    Redman, B. G.
    Hudes, G. R.
    Bukowski, R. M.
    Kim, S. T.
    Chen, I.
    Wilding, G.
    Motzer, R. J.
    EJC SUPPLEMENTS, 2007, 5 (04): : 304 - 304
  • [8] Presurgical sunitinib in patients with newly diagnosed metastatic renal cell carcinoma (mRCC): Interim toxicity and feasibility analysis
    Jonasch, E.
    Wood, C. G.
    Pagliaro, L. C.
    Corn, P. G.
    Aparicio, A.
    Marcott, V. D.
    Matin, S. F.
    Tannir, N. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [9] Biological toxicity as a predictive factor of efficacy in metastatic renal cell carcinoma (mRCC) treated with sunitinib
    Guillabert, P.
    Elaidi, R. T.
    Teghom, C.
    Medioni, J.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S651 - S651
  • [10] Is there a "trial effect" on outcome of patients with metastatic renal cell carcinoma (mRCC) treated with sunitinib?
    Keizman, Daniel
    Ish-Shalom, Maya
    Maimon, Natalie
    Gottfried, Maya
    Pili, Roberto
    Hammers, Hans J.
    Eisenberger, Mario A.
    Sinibaldi, Victoria J.
    Boursi, Ben
    Weitzen, Rony
    Hayat, Henry
    Peer, Avivit
    Neumann, Avivit
    Kovel, Svetlana
    Sella, Avishay
    Mermershtain, Wilmosh
    Roubinov, Keren
    Carducci, Michael Anthony
    Berger, Raanan
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
12345